Van Lanschot Kempen Investment Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$42.3M Sell
45,972
-5,026
-10% -$5.1M 0.37% 46
2025
Q4
$54.8M Buy
50,998
+2,626
+5% +$2.51M 0.47% 34
2025
Q3
$36.9M Buy
48,372
+3,469
+8% +$2.58M 0.33% 53
2025
Q2
$35M Sell
44,903
-5,841
-12% -$4.54M 0.33% 53
2025
Q1
$41.9M Buy
50,744
+21,940
+76% +$18.3M 0.44% 51
2024
Q4
$22.2M Buy
28,804
+7,255
+34% +$6.01M 0.22% 103
2024
Q3
$19.1M Buy
21,549
+461
+2% +$414K 0.19% 116
2024
Q2
$19.1M Buy
+21,088
New +$16.9M 0.21% 105
2023
Q2
Sell
-150
Closed -$51.5K 217
2023
Q1
$51.5K Hold
150
﹤0.01% 197
2022
Q4
$54.9K Sell
150
-48
-24% -$17K ﹤0.01% 192
2022
Q3
$64K Buy
198
+11
+6% +$3.48K ﹤0.01% 191
2022
Q2
$61K Sell
187
-32
-15% -$9.61K ﹤0.01% 191
2022
Q1
$63K Sell
219
-128
-37% -$32.9K ﹤0.01% 186
2021
Q4
$96K Sell
347
-46
-12% -$11.7K ﹤0.01% 174
2021
Q3
$91K Buy
393
+17
+5% +$4.2K ﹤0.01% 187
2021
Q2
$86K Buy
+376
New +$75.5K ﹤0.01% 183
2014
Q2
Sell
-8,800
Closed -$517K 99
2014
Q1
$517K Hold
8,800
0.05% 89
2013
Q4
$448K Buy
+8,800
New +$441K 0.04% 91

Other funds holding LLY

Van Lanschot Kempen Investment Management's LLY Position: Q1 2026 in Review

Van Lanschot Kempen Investment Management reduced its Eli Lilly (LLY) stake by 9.9% in Q1 2026, selling an estimated $5.1M and leaving 45,972 shares worth $42.3M. The position accounts for 0.37% of the portfolio, ranked #46.

Van Lanschot Kempen Investment Management first reported a position in LLY in Q4 2013 and has held it in 18 quarters since. The position peaked at $54.8M in Q4 2025. 4,360 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Van Lanschot Kempen Investment Management held 45,972 shares of Eli Lilly worth $42.3M as of Q1 2026.
  • Van Lanschot Kempen Investment Management sold 5,026 Eli Lilly shares in Q1 2026, an estimated $5.1M.
  • Eli Lilly made up 0.37% of Van Lanschot Kempen Investment Management's portfolio in Q1 2026, its #46 holding.
  • Van Lanschot Kempen Investment Management first reported a position in Eli Lilly in Q4 2013 and has held it in 18 quarters since.
  • Van Lanschot Kempen Investment Management's Eli Lilly position peaked at $54.8M in Q4 2025.
  • 4,360 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Van Lanschot Kempen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.